Finding the best hydroxyurea dose for sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how people of Nigerian descent with sickle cell disease respond to hydroxyurea, a medicine that helps prevent painful episodes. The goal is to see how your genetic makeup affects how the drug works so that doctors can find the best dose for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sickle cell disease (for example, HbSS or HbSC) and are of Nigerian descent.
- You either already take hydroxyurea (a medicine to manage sickle cell) or are willing to start taking it.
- You have had a test to check how your body processes certain medications, such as a CYP2D6 test.
- You are willing to give your consent to join the study.
- You do not have severe kidney or liver problems, are not in an acute (sudden) sickle cell crisis, and have a history of taking medications as directed.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.